GLIMIMED V

CARDIO-DIABETIC

GLIMIMED V

Glimepiride 2 mg + Metformin 500 mg SR + Voglibose 0.2 mg Bilayered Tab

Glimepiride 2mg + Metformin 500mg SR + Voglibose 0.2mg is a fixed-dose combination drug that controls type 2 diabetes.

Glimepiride 2mg + Metformin 500mg SR + Voglibose 0.2mg is a fixed-dose combination drug that controls type 2 diabetes. The drug controls blood sugar by activating the secretion of insulin, inhibiting the production of glucose, enhancing insulin sensitivity, and slowing down the absorption of carbohydrates, avoiding sudden increases in blood sugar following food intake.

MRP: ₹2050/-

Uses

Side Effects

Nausea, bloating, or discomfort in the stomach.
Hypoglycemia (low blood sugar) with dizziness or perspiration.
Diarrhea or mild gastrointestinal disturbance.
Flatulence as a result of the activity of Voglibose.

Indications

Effective control of blood sugar in type 2 diabetes.
Improves glucose metabolism and insulin secretion.
Decreases post-meal blood sugar rise by delaying carbohydrate absorption.
Decreases the risk of diabetic complications.

FAQ

Q1. What is the mechanism of this combination in diabetes?
Ans. Glimepiride increases insulin secretion, Metformin decreases glucose production, and Voglibose delays carbohydrate absorption, maintaining stable blood sugar levels.

Q2. At what time should I take this tablet?
Ans. It must be taken before or with meals to achieve optimal effectiveness in suppressing blood sugar surges.

Q3. Can this drug lead to low blood sugar?
Ans. Yes, particularly when taken on an empty stomach or with other diabetes drugs. Blood sugar should be monitored regularly.

Q4. Is it safe to take for the long term?
Ans. Yes, provided there is ongoing blood sugar monitoring and assessment of kidney function to ensure safe and effective treatment.